GPR35 and inflammatory bowel disease: GPR35 is a recently deorphanized GPCR that has been suggested as a novel therapeutic target based on the association between GPR35 polymorphisms and various pathologies,18,19 including heart failure,20–23 diabetes,24 inflammatory bowel disease,25 and cancer.26 We reported that GPR35 participated in experimental colitis by modulating the inflammatory response.27 However, the precise function of GPR35 in the cardiovascular system remains to be elucidated.